Potent peptidic fusion inhibitors of influenza virus

Science

Volumn 358, Issue 6362, 2017, Pages 496-502

  Kadam, Rameshwar U ^a   Juraszek, Jarek ^b   Brandenburg, Boerries ^b   Buyck, Christophe ^c   Schepens, Wim B G ^c   Kesteleyn, Bart ^d   Stoops, Bart ^c   Vreeken, Rob J ^c   Vermond, Jan ^b   Goutier, Wouter ^b   Tang, Chan ^b   Vogels, Ronald ^b   Friesen, Robert H E ^b,f   Goudsmit, Jaap ^b,e   Van Dongen, Maria J P ^b,c   Wilson, Ian A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Janssen Prevention Center   (Netherlands)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Janssen Research and Development   (Netherlands)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f PROQR THERAPEUTICS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PEPTIDE P7; UNCLASSIFIED DRUG; VIRUS FUSION INHIBITOR; ANTIVIRUS AGENT;

INFLUENZA; INHIBITOR; NEUTRALIZATION; PEPTIDE; VIRUS;

ANIMAL EXPERIMENT; ARTICLE; DRUG PROTEIN BINDING; DRUG STRUCTURE; HUMAN; IC50; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA VIRUS; MALE; MOUSE; NONHUMAN; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COMPLEMENTARITY DETERMINING REGION; DRUG DESIGN; DRUG EFFECTS; PROTEIN CONFORMATION; VIRUS ENTRY; X RAY CRYSTALLOGRAPHY;

AVES; ORTHOMYXOVIRIDAE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; COMPLEMENTARITY DETERMINING REGIONS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MALE; MICE; MICE, INBRED BALB C; PEPTIDES, CYCLIC; PROTEIN CONFORMATION; VIRUS INTERNALIZATION;

EID: 85030554419     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aan0516     Document Type: Article

References (28)

1. K. Das, J. M. Aramini, L. C. Ma, R. M. Krug, E. Arnold, Nat. Struct. Mol. Biol. 17, 530-538 (2010).
2. E. De Clercq, Nat. Rev. Drug Discov. 5, 1015-1025 (2006).
3. A. Moscona, N. Engl. J. Med. 360, 953-956 (2009).
4. T. G. Sheu et al., J. Infect. Dis. 203, 13-17 (2011).
5. J. J. Skehel, D. C. Wiley, Annu. Rev. Biochem. 69, 531-569 (2000).
6. I. A. Wilson, J. J. Skehel, D. C. Wiley, Nature 289, 366-373 (1981).
7. P. A. Bullough, F. M. Hughson, J. J. Skehel, D. C. Wiley, Nature 371, 37-43 (1994).
8. J. P. Julien, P. S. Lee, I. A. Wilson, Immunol. Rev. 250, 180-198 (2012).
9. P. S. Lee, I. A. Wilson, Curr. Top. Microbiol. Immunol. 386, 323-341 (2014).
10. C. Dreyfus et al., Science 337, 1343-1348 (2012).
11. S. J. Fleishman et al., Science 332, 816-821 (2011).
12. T. A. Whitehead et al., Nat. Biotechnol. 30, 543-548 (2012).
13. M. T. Koday et al., PLOS Pathog. 12, e1005409 (2016).
14. D. J. Craik, D. P. Fairlie, S. Liras, D. Price, Chem. Biol. Drug Des. 81, 136-147 (2013).
15. E. Sparrow, M. Friede, M. Sheikh, S. Torvaldsen, A. T. Newall, Vaccine 34, 5442-5448 (2016).
16. F. Casset et al., Biochem. Biophys. Res. Commun. 307, 198-205 (2003).
17. W. V. Williams, T. Kieber-Emmons, J. VonFeldt, M. I. Greene, D. B. Weiner, J. Biol. Chem. 266, 5182-5190 (1991).
18. M. Levi et al., Proc. Natl. Acad. Sci. U.S.A. 90, 4374-4378 (1993).
19. D. C. Ekiert et al., Science 324, 246-251 (2009).
20. J. Sui et al., Nat. Struct. Mol. Biol. 16, 265-273 (2009).
21. A. K. Kashyap et al., PLOS Pathog. 6, e1000990 (2010).
22. D. Corti et al., Science 333, 850-856 (2011).
23. A. Wyrzucki et al., J. Virol. 88, 7083-7092 (2014).
24. G. Nakamura et al., Cell Host Microbe 14, 93-103 (2013).
25. Y. N. Imai, Y. Inoue, I. Nakanishi, K. Kitaura, Protein Sci. 17, 1129-1137 (2008).
26. R. J. Russell et al., Virology 325, 287-296 (2004).
27. R. U. Kadam, I. A. Wilson, Proc. Natl. Acad. Sci. U.S.A. 114, 206-214 (2017).
28. B. Brandenburg et al., PLOS ONE 8, e80034 (2013).